Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]
J Hepatol
.
2022 Dec;77(6):1731-1732.
doi: 10.1016/j.jhep.2022.07.001.
Epub 2022 Jul 8.
Authors
Sergio Maimone
1
,
Vincenzo Francesco Tripodi
2
,
Anna Teresa Mazzeo
3
Affiliations
1
Division of Medicine and Hepatology, University Hospital of Messina, Messina, Italy. Electronic address: smaimone@unime.it.
2
Surgery Department, Anesthesia and Intensive Care, University Hospital of Messina, Messina, Italy.
3
Human Pathology Department, Anesthesia and Intensive Care, University Hospital of Messina, Messina, Italy.
PMID:
35810928
DOI:
10.1016/j.jhep.2022.07.001
No abstract available
Publication types
Letter
Comment
MeSH terms
Albumins
Humans
Hypotension, Controlled*
Liver Cirrhosis / complications
Randomized Controlled Trials as Topic
Sepsis* / complications
Substances
Albumins
Plasma-lyte 148